Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Recommendations for the Prevention and Treatment of CIPN

Web Exclusives
Brian D. McMichael, MD
Assistant Professor-Clinical, Department of Physical Medicine & Rehabilitation, Ohio State University, Columbus, OH

The American Society of Clinical Oncology recommendations for the prevention and management of chemotherapy-induced peripheral neuropathy (CIPN) in survivors of adult cancers include:

  • No established agents are recommended for preventing CIPN, because of the lack of high-quality, consistent evidence and a balance of benefits versus harms
  • The following agents should not be offered for the prevention of CIPN: Ethyol (amifostine), Elavil (amitriptyline), calcium plus magnesium, diethyldithiocarbamate, Tationil (glutathione), Nimotop (nimodipine), Org 2766, Atralin (tretinoin), rhuLIF, and vitamin E; acetyl-L-carnitine has been associated with worse long-term outcomes for CIPN
  • Treating clinicians can offer Cymbalta (duloxetine) to patients with CIPN
  • Although recommendations cannot be made for tricyclic antidepressants, Neurontin (gabapentin), or topical gels containing Lioresal (baclofen), Elavil (amitriptyline), and Ketalar (ketamine) because of the lack of strong evidence, it might be reasonable to try them in select patients

Source: Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941-1967.

Recommended For You